Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shari Pilon-Thomas

Showing results (91-100 of 101) with videos related to

Pageof 11
Sort By:
Journal of Clinical Virology Plus|September 1, 2023
SARS-CoV-2 antibody response duration and neutralization following natural infectionChristopher W Dukes, Renata Am Rossetti, Jonathan A Hensel, et al.
Vaccines|January 22, 2024
Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer PatientsChristopher W Dukes, Marine Potez, Jeffrey Lancet, et al.
Biorxiv : the Preprint Server for Biology|January 8, 2024
Branched-chain keto acids promote an immune-suppressive and neurodegenerative microenvironment in leptomeningeal diseaseMariam Lotfy Khaled, Yuan Ren, Ronak Kundalia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2022
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic MelanomaMacLean S Hall, John E Mullinax, Cheryl A Cox, et al.
Biorxiv : the Preprint Server for Biology|October 28, 2024
Nanoparticles use magnetoelectricity to target and eradicate cancer cellsJohn Michael Bryant, Emmanuel Stimphil, Victoria Andre, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|November 3, 2025
Magnetoelectric Nanotherapy Achieves Complete Tumor Ablation and Prolonged Survival in Pancreatic Cancer Murine ModelsJohn Michael Bryant, Max Shotbolt, Emmanuel Stimphil, et al.
Immunity|April 16, 2020
The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING SignalingEslam Mohamed, Rosa A Sierra, Jimena Trillo-Tinoco, et al.
Journal for Immunotherapy of Cancer|October 6, 2023
Neoantigen-specific CD4<sup>+</sup> tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patientsMacLean S Hall, Jamie K Teer, Xiaoqing Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2022
Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic MelanomaCaitlin A Creasy, Yuzhong Jeff Meng, Marie-Andrée Forget, et al.
Frontiers in Immunology|December 3, 2025
Case Report: Durable response to tumor-infiltrating lymphocyte therapy in a patient with metastatic melanoma and chronic lymphocytic leukemia/small lymphocytic lymphomaLilit Karapetyan, Joel Kuriakose, Matthew C Perez, et al.
Pageof 11

Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
Journal of Clinical Virology Plus|September 1, 2023
SARS-CoV-2 antibody response duration and neutralization following natural infectionChristopher W Dukes, Renata Am Rossetti, Jonathan A Hensel, et al.
Vaccines|January 22, 2024
Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer PatientsChristopher W Dukes, Marine Potez, Jeffrey Lancet, et al.
Biorxiv : the Preprint Server for Biology|January 8, 2024
Branched-chain keto acids promote an immune-suppressive and neurodegenerative microenvironment in leptomeningeal diseaseMariam Lotfy Khaled, Yuan Ren, Ronak Kundalia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2022
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic MelanomaMacLean S Hall, John E Mullinax, Cheryl A Cox, et al.
Biorxiv : the Preprint Server for Biology|October 28, 2024
Nanoparticles use magnetoelectricity to target and eradicate cancer cellsJohn Michael Bryant, Emmanuel Stimphil, Victoria Andre, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|November 3, 2025
Magnetoelectric Nanotherapy Achieves Complete Tumor Ablation and Prolonged Survival in Pancreatic Cancer Murine ModelsJohn Michael Bryant, Max Shotbolt, Emmanuel Stimphil, et al.
Immunity|April 16, 2020
The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING SignalingEslam Mohamed, Rosa A Sierra, Jimena Trillo-Tinoco, et al.
Journal for Immunotherapy of Cancer|October 6, 2023
Neoantigen-specific CD4<sup>+</sup> tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patientsMacLean S Hall, Jamie K Teer, Xiaoqing Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2022
Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic MelanomaCaitlin A Creasy, Yuzhong Jeff Meng, Marie-Andrée Forget, et al.
Frontiers in Immunology|December 3, 2025
Case Report: Durable response to tumor-infiltrating lymphocyte therapy in a patient with metastatic melanoma and chronic lymphocytic leukemia/small lymphocytic lymphomaLilit Karapetyan, Joel Kuriakose, Matthew C Perez, et al.
Pageof 11